Exabis Library
Welcome to the e-CCO Library!
P443: Trough concentration response in infliximab and adalimumab treated children with IBD following treatment adjustment: A pharmacokinetic model.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P444 The impact of azathioprine on inflammatory bowel disease patients’ overall health-related quality of life: a single-centre retrospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P444: A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes assessed
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P444: COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P444: Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P444: Fecal calprotectin response to anti-tumor necrosis factor alpha induction and maintenance in Pediatric Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P444: High-dose intravenous iron isomaltoside infusion is not associated with an increase in intact fibroblast growth factor 23 (iFGF23) in patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P444: Post-induction Infliximab trough levels in severe and moderate paediatric ulcerative colitis: preliminary data of a retrospective, population cohort-based study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P445 Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with vedolizumab in severe ulcerative colitis: a large patient cohort with long-term follow-up
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P445: Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P445: Early outcomes for adolescent inflammatory bowel disease patients treated in a transition clinic
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P445: Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from Hungary
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P445: Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P445: Patients with active perianal fistulas have a reduced physical health compared with Crohn’s patients without perianal fistulas
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P445: Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P445: Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P446: Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P446: Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P446: Effects of CYP3A5 genotype on efficacy and safety of tacrolimus in refractory ulcerative colitis: experience from a tertiary referral centre
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM